You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Details for Patent: 8,618,064


✉ Email this page to a colleague

« Back to Dashboard


Title:Methods of providing therapeutic effects using cyclosporin components
Abstract: Methods of treating an eye of a human or animal include administering to an eye of a human or animal a composition in the form of an emulsion including water, a hydrophobic component and a cyclosporin component in a therapeutically effective amount of less than 0.1% by weight of the composition. The weight ratio of the cyclosporin component to the hydrophobic component is less than 0.8.
Inventor(s): Acheampong; Andrew (Irvine, CA), Tang-Liu; Diane (Newport Beach, CA), Chang; James N. (Newport Beach, CA), Power; David F. (Trabuco Canyon, CA)
Assignee: Allergan, Inc. (Irvine, CA)
Filing Date:Aug 28, 2007
Application Number:11/897,177
Claims:1. A method of treating or preventing corneal graft rejection, the method comprising administering to an eye of a human or animal in need thereof, at a frequency of once per day, a composition in the form of an emulsion comprising water, polysorbate 80, a hydrophobic component, and a cyclosporin component in a therapeutically effective amount equal to or less than 0.05% by weight of the composition, wherein the weight ratio of the cyclosporin component to the hydrophobic component is less than 0.08.

2. The method of claim 1 wherein the blood of the human or animal has no detectable concentration of the cyclosporin component.

3. The method of claim 1 wherein the blood of the human or animal has substantially no detectable concentration of the cyclosporin component as measured using a validated liquid chromatographylmass spectrometry analytical method.

4. The method of claim 1 wherein the blood of the human or animal has a concentration of the cyclosporin component of 0.1 ng/ml or less.

5. The method of claim 1 wherein the cyclosporin component comprises a material selected from cyclosporin A, derivatives of cyclosporin A and mixtures thereof.

6. The method of claim 1 wherein the cyclosporin component comprises cyclosporin A.

7. The method of claim 1 wherein the cyclosporin component is solubilized in the hydrophobic component present in the composition.

8. The method of claim 1 wherein the hydrophobic component is present in the composition in an amount greater than 0.625% by weight of the composition.

9. The method of claim 1 wherein the hydrophobic component comprises an oily material.

10. The method of claim 1 wherein the hydrophobic component comprises an ingredient selected from the group consisting of vegetable oils, animal oils, mineral oils, synthetic oils and mixtures thereof.

11. The method of claim 1 wherein the hydrophobic component comprises castor oil.

12. The method of claim 1 wherein the administering step comprises topically administering the composition to the eye of the human.

13. The method of claim 1 wherein the composition comprises an effective amount of a tonicity component.

14. The method of claim 1 wherein the composition comprises an effective amount of an organic tonicity component.

15. The method of claim 1 wherein the composition comprises a polyelectrolyte component in an amount effective in stabilizing the composition.

16. The method of claim 1 wherein the composition has a pH in the range of about 7.0 to about 8.0.

17. The method of claim 1 wherein the composition has a pH in the range of about 7.2 to about 7.6.

18. The method of claim 1, where the cyclosporin component is in a therapeutically effective amount of less than 0.05% by weight of the composition.

19. The method of claim 1, wherein the cyclosporin component is in a therapeutically effective amount of 0.05% by weight of the composition.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.